Evidence map›Paper›PMID 32569653›Full record

ArticleKidney international2020

Deletion of the myeloid endothelin-B receptor confers long-term protection from angiotensin II-mediated kidney, eye and vessel injury.

Léa Guyonnet, Alicja Czopek, Tariq E Farrah, Véronique Baudrie, Philippe Bonnin, Anna Chipont, Olivia Lenoir, Florian Sennlaub, Christophe Roubeix, David J Webb and 4 more

Open access · bronzeAbstract read
In one paragraph

Article in Kidney international, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.0field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Insights Into Stria Vascular Function, Stria Immunity, and Age-Related Hearing Loss.Journal of the Association for Research in Otolaryngology : JARO · 2025
    Review
  3. Article
  4. Immune and inflammatory mechanisms in hypertension.Nature reviews. Cardiology · 2024
    Review
  5. Endothelin System in Hypertension and Chronic Kidney Disease.Hypertension (Dallas, Tex. : 1979) · 2024
    Review
  6. Article
  7. Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 2 countries.

Léa GuyonnetParis Cardiovascular Research Centre-PARCC, Institut National de la Santé et de la Recherche Médicale (INSERM), Université de Paris, Paris, France.
Alicja CzopekUniversity/BHF Centre of Research Excellence, University of Edinburgh, The Queen's Medical Research Institute, Edinburgh, UK.
Tariq E FarrahUniversity/BHF Centre of Research Excellence, University of Edinburgh, The Queen's Medical Research Institute, Edinburgh, UK.
Véronique BaudrieParis Cardiovascular Research Centre-PARCC, Institut National de la Santé et de la Recherche Médicale (INSERM), Université de Paris, Paris, France.
Philippe BonninINSERM U1275 & Physiologie Clinique, Hôpital Lariboisière, Université de Paris, Paris, France.
Anna ChipontParis Cardiovascular Research Centre-PARCC, Institut National de la Santé et de la Recherche Médicale (INSERM), Université de Paris, Paris, France.
Olivia LenoirParis Cardiovascular Research Centre-PARCC, Institut National de la Santé et de la Recherche Médicale (INSERM), Université de Paris, Paris, France.
Florian SennlaubInstitut National de la Santé et de la Recherche Médicale, Institut de la Vision, Paris, France.
Christophe RoubeixInstitut National de la Santé et de la Recherche Médicale, Institut de la Vision, Paris, France.
David J WebbUniversity/BHF Centre of Research Excellence, University of Edinburgh, The Queen's Medical Research Institute, Edinburgh, UK.
David C KluthUniversity/BHF Centre of Research Excellence, University of Edinburgh, The Queen's Medical Research Institute, Edinburgh, UK.
Matthew A BaileyUniversity/BHF Centre of Research Excellence, University of Edinburgh, The Queen's Medical Research Institute, Edinburgh, UK.
Pierre-Louis TharauxParis Cardiovascular Research Centre-PARCC, Institut National de la Santé et de la Recherche Médicale (INSERM), Université de Paris, Paris, France. Electronic address: pierre-louis.tharaux@inserm.fr.
Neeraj DhaunParis Cardiovascular Research Centre-PARCC, Institut National de la Santé et de la Recherche Médicale (INSERM), Université de Paris, Paris, France; University/BHF Centre of Research Excellence, University of Edinburgh, The Queen's Medical Research Institute, Edinburgh, UK. Electronic address: bean.dhaun@ed.ac.uk.
Inserm · FREdinburgh College · GBInstitut de la Vision · FR

Funding

British Heart Foundation FS/13/30/29994Medical Research Council MR/R017840/1
6 · The paper itself

Abstract

The endothelin system may be an important player in hypertensive end-organ injury as endothelin-1 increases blood pressure and is pro-inflammatory. The immune system is emerging as an important regulator of blood pressure and we have shown that the early hypertensive response to angiotensin-II infusion was amplified in mice deficient of myeloid endothelin-B (ET

Indexed as

Angiotensin IIHypertensionAnimalsBlood PressureEndothelinsKidneyMiceReceptor, Endothelin BAngiotensin IIEndothelinsReceptor, Endothelin Bendothelinhypertensionmacrophagesorgan injury

Identifiers

PMID32569653
PMCPMC7652550
OpenAlexW3036478371

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.